Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZSA-215
- Development stage
- Unknown
- Lead developer
- University of Michigan
01
Overview
ZSA-215: sourced facts only. name: "These results suggest that ZSA-215 is a potent oral STING agonist warrant further development for cancer immunotherapy." [PMID:40442142]; target: "These results suggest that ZSA-215 is a potent oral STING agonist warrant further development for cancer immunotherapy." [PMID:40442142]; developer: "Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States." [PMID:40442142]; stage: "Notably, monotherapy of oral ZSA-215 achieved complete tumor regression and long-term survival of mice in MC38 colon cancer model, which is superior to MSA-2." [PMID:40442142]
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on ZSA-215.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZSA-215.